European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for Alzheimer’s disease, providing a response after a meeting next month.
Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the March 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay ...
The Papua New Guinea government is reportedly ready to pass a legislation to regulate its media, which journalism advocates have said could have serious implications for democracy and freedom of ...
Patients and care partners may find once every four weeks maintenance dosing easier The US Food and Drug Administration (FDA) has approved Eisai and Biogen’s Supplemental Biologics License Application ...
Versant Ventures has made its fourth investment in an obesity startup in eight months, co-leading a $65 million Series A round in Helicore Biopharma, a developer of an antibody drug that blocks a gut ...
Sage Therapeutics knows it needs to do something. But it doesn’t want to sell to its partner Biogen.
After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. However, the company's board of directors ...
Eisai and Biogen scored an approval for once-monthly IV maintenance dosing of their Alzheimer’s drug Leqembi, as part of what they’ve said is an ongoing … ...
(Reuters) -Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback